The Differences Between Tumor Necrosis Factor-α (TNF-α) Expression in Fleshy and Atrophy Pterygium
Article Sidebar
Abstract
Background: Pterygium is a conjungtival fibrovascular degenerative process which fleshy type was different to atrophy type, in which post operative recurrencies was high especially fleshy type. The exact pathogenesis were not clearly understood, it was reported that many inflammation mediators had a play role, including Tumor Necrosis Factor-α (TNF-α). Objective of the study was to revealed a different expression of TNF-α in fleshy and atrophy type.
Method: Cross-sectional study design have been done with independent variable was TNF-α and dependant vaiable was pterygium type. Samples consist of 20 patients fleshy type and 20 patients atrophy type, both groups were given fluorometholone eye drop for 1 week prior surgery to suppress the degree of inflammation. The baseline data was recorded e.g. demography, the size of pterygium, Tear Break Up Time (TBUT), Schirmer test and Ferning test. Pterygium excission followed by limbal stem cell graft, and examination of TNF-α expression by immunohistochemistry. TNF-α expression was analyzed using 2 x 2 table.
Result: Baseline data of both groups were not significantly different, except TBUT (p=0.000) and the clinical characteristic of pterygium (p=0.000). TNF-α expression in fleshy type tend to be higher (total Allred score mean 4.70) but not significantly different than atrophic type (total Allred score mean 4.54 and p=0.61). Previous fluorometholone treatment prior to surgery might be suppressed the inflammatory cytokine.
Conclusion: No significant difference of the TNF-α expressions between fleshy and atrophy type of pterygium.
Keywords: pterygium, fleshy type, atrophy type, TNF-α, immunohistochemistry
Full text article
References
Tan DTH. Pterigium. In: Edward J. Holland, Mark J. Mannis, Ocular Surface Disease Medical and Surgical Management: Springer-Verlag New York, Inc; 2002:65-89.
Asokan R, Venkatasubbu RS, Velumuri L, Lingam V, George R. Prevalence and associated factors for pterigium and pinguecula in a South Indian population. Ophthalmic Physiol Opt. 2012;32(1):39-44.
Peckar CO. The aetiology and histo-pathogenesis of pterigium. A review of the literature and a hypothesis. Documenta Ophthalmologica Advances in Ophthalmology. 1972;31(1):141-57.
Anduze AL. Pterigium: A Practical Guide to Management. Jaypee Brothers Medical Publishers (P) Ltd: New Delhi; 2009:23-33.
Soediro S, Natadisastra G, Supardi I, Hernowo BS, Maskoen AM. Hypersensitivity Reaction in Inflamed Pterigium.2011. Available from: http://www.mkb-online.org/index.php?option=com_conte nt&view=article&id=366:hypersensitivity-reaction-in-inflamed-pterigium-&catid=1:kumpulan-artikel&Itemid=55.
Mutlu FM, Sobaci G, Tatar T, Yildirim E. A comparative study of recurrent pterigium surgery: limbal conjunctival autograft transplantation versus mitomycin C with conjunctival flap. Ophthalmology. 1999;106(4):817-21.
Tsai YY, Lee H, Tseng SH, Cheng YW, Tsai CH, Hsu CM, et al. Evaluation of TNF-alpha and IL-1beta polymorphisms in Taiwan Chinese patients with pterigium. Eye (Lond). 2005;19(5):571-4.
Di Girolamo N, Wakefield D, Coroneo MT. UVB-mediated induction of cytokines and growth factors in pterigium epithelial cells involves cell surface receptors and intracellular signaling. Investigative ophthalmology & visual science. 2006;47(6):2430-7.
Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterigium epithelial cells. Investigative ophthalmology & visual science. 2002;43(11):3430-7.
Kollias G, Sfikakis PP. Preface. In: TNF pathophysiology: molecular and cellular mechanisms. Karger: Basel;2010. VIIp.
Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterigium. Acta histochemica. 1996;98(2):195-201.
Siak JJ, Ng SL, Seet LF, Beuerman RW, Tong L. The nuclear-factor kappaB pathway is activated in pterigium. Investigative ophthalmology & visual science. 2011;52(1):230-6.
Li DQ, Lee SB, Gunja-Smith Z, Liu Y, Solomon A, Meller D, et al. Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterigium head fibroblasts. Archives of ophthalmology. 2001;119(1):71-80.
Zeng J, Jiang D, Liu X, Tang L. [Expression of matrix metalloproteinase in human pterygia]. Yan ke xue bao = Eye science / “Yan ke xue bao†bian ji bu. 2004;20(4):242-5. Epub 2005/01/20.
Zhang J, Jin W, Lin Y, Zhang G. [Cytokine assays for pterigium]. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology. 1999;35(1):16-8.
Zhang J, Jin W, Lin Y, Zhang G. Significance of the abnormal secretion of IL-6 and TNF-α in the pterigium [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 1999;15.
Zakaria N, De Groot V, Tassignon MJ. Tear film biomarkers as prognostic indicators for recurrent pterigium. Bulletin de la Societe belge d’ophtalmologie. 2011(317):53-4.
Zhu L, Zhang C, Chuck RS. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. Molecular vision. 2012;18:1803-12.
Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annual review of genomics and human genetics. 2001;2:9-39.
Baratawidjaja KG, Rengganis I. Imunologi dasar. Edisi ke delapan. Balai penerbit Fakultas Kedokteran Universitas Indonesia Jakarta, 2009:217–55.